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Abstract
Background: Popular medicine has been used to treat some diseases 
including mental disorders since the ancient times. The development 
of this powerful tool can bring to the actual world some benefits to 
improve the way of taking care of mental illnesses.
Objective: To show relevant studies about biopharmaceuticals and 
to infer the equivalence of using biopharmaceuticals, regarding to 
efficacy and safety as the chemical-type drugs in the treatment for 
mental disorders, assessing whether there are biomolecules that 
might work as biopharmaceuticals to treat, cure or mitigate diffe-
rent mental disorders.
Methods: A systematic review from 01.01.2004 to 25.28.2014 was 
performed on the databases PubMed, Scopus and Science Direct. 
The search was performed with the descriptor ''mental disorders'' 
and with the keywords ''biopharmaceuticals'' and ''biomolecules''. 
The information pertinent to the study was selected, categorized and 
analyzed. Of the 339 articles found, 20 met the eligibility criteria.
Results: Eastern culture, followed by Amazonian region concentrated 
most of the species related with popular treatment of mental disor-
ders. Several species were revealed to act upon receptors or neuro-
transmitters in the Central Nervous System (CNS), which, sometimes, is 
a similar mechanism of action of a lot of well-known synthetic drugs 
on the market. It was also highlighted the use of the genetic knowled-
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Introduction
It is estimated that 70% to 80% of people worldwi-
de rely chiefly on traditional, largely herbal medicine 
to meet their primary health care needs. It has fur-
ther been observed that a number of modern phar-
maceuticals have been derived from plants used by 
indigenous people. Many modern drugs have been 
derived from observations of traditional medicinal 
use including aspirin, atropine, ephedrine, digoxin, 
morphine, quinine, reserpine, and tubocurarine. Out 
of the 350,000 plant species identified so far, about 
35,000 (some estimated up to 70,000) are used 
worldwide for medicinal purposes, and less than 
about 0.5% of these have been chemically investi-
gated [1, 2-8]. 
Taken together the major mental disorders, schi-
zophrenia and bipolar disorder, affect almost 2% 
of the adult population and are a major cause of 
global disability. In the absence of a clear understan-
ding of the pathophysiological processes involved, 
diagnosis is based on a clinical assessment of symp-
toms (e.g., delusions, hallucinations, depression and 
mania) and course of illness. Both disorders are still 
associated with substantial morbidity and prematu-
re mortality. The statistics are sobering: people with 
severe mental illness die on average 25 years earlier 
than those in the general population. Intensive in-
vestigation of known mood stabilizers (e.g., lithium) 
and antipsychotic medications (e.g., haloperidol and 
clozapine) has yet to translate into better understan-
ding of aetiology or a breakthrough in development 
of new therapies leading to improved outcome [9]. 
Numerous psychological and brain disorder re-
search studies have been conducted using tradi-
tional medicinal plants in the form of specific oils, 
herbal extracts, and combinations to treat specific 
diseases, including anxiety, depression, insomnia, 
Alzheimer’s, convulsions, Parkinson’s, etc. in an 
effort to discover new therapeutic agents that lack 
the toxic side effects associated with the current 
agents [10]. 
Various plant-derived essential oils (EOs) have 
been used in European, Arabic, and Mediterranean 
countries for the treatment of different illnesses [11, 
12, 13]. India and China are the countries of vast 
biodiversity and traditional knowledge for using na-
tural/herbal medicines to cure many ailments in va-
rious cultures and tribes. There has been a conside-
rable popular interest in the use of herbal products, 
to treat anxiety disorder/reactions [10]. One possible 
explanation for the efficacy of EOs for mental disor-
ders is that EOs may have central nervous system 
(CNS) acting effects [11, 14]. 
The search for new psychotropic medications for 
the treatment of diseases of the nervous system 
and mental illnesses has benefited enormously from 
ethnopharmacology. In the field of psychopharma-
ge to propose a gene therapy, in which a more targeted treatment 
would be available in cases of mental illnesses.
Conclusion: Our findings consolidate the importance of popular 
medicine to society. In this study, the reported natural compounds 
have been used for many years to treat mental disorders confirming 
their potential activity as biopharmaceuticals. Also, possible targets 
were reported for gene therapy, a promising approach to treat mental 
illnesses.
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cology, ethnopharmacological research has unco-
vered a wide spectrum of CNS-active compounds 
ranging from sedatives to anxiolytics to analgesics 
to hallucinogens [15]. 
Depression is a serious public mental disease. It 
is a major cause of disability, suicide and physical 
disorders [16, 17]. Depressive disorder is a preva-
lent psychiatric disorder, which affects 21% of the 
world population [18, 19]. In search for new the-
rapeutic products for the treatment of depression, 
medicinal plant research has contributed signifi-
cantly by demonstrating pharmacological effecti-
veness of different herbs or their prescriptions [20, 
21, 22]. 
Anxiety disorders are among the most common 
types of mental illnesses [23, 24] with a 12-month 
prevalence of approximately 17% and a lifetime 
prevalence of almost 25% in the USA [23, 25]. 
Despite its high prevalence, anxiety disorder is 
a seriously undertreated condition, and a recent 
mental health survey suggests that more than half 
of affected patients do not receive appropriate 
treatment [23, 26]. 
The most commonly used drugs in the pharma-
cological treatment of anxiety are serotonin reup-
take inhibitors (SRIs) and benzodiazepines [23, 27]. 
Fragile X syndrome, the most common cause of 
inherited mental retardation and autism spectrum 
disorders, is caused by mutations of the FMR1 gene 
that encodes the fragile X mental retardation pro-
tein (FMRP) [28, 29-37].
Medications such as tricyclic antidepressants 
(TCAs), selective serotonin reuptake inhibitors (SSRIs), 
selective reversible inhibitors of monoamine oxida-
se A (RIMAs), and specific serotonin–noradrenaline 
reuptake inhibitors (SNRIs) are clinically employed 
for drug therapy [18, 38]. Also, they can impose 
a variety of side-effects including cardiac toxicity, 
hypopiesia, sexual dysfunction, body weight gain, 
and sleep disorder [18, 39-42]. 
The present review intends to show relevant 
studies about biopharmaceuticals and to infer the 
equivalence of using biopharmaceuticals, regarding 
to efficacy and safety as the chemical-type drugs 
in the treatment for mental disorders, assessing 
whether there are biomolecules that might work 
as biopharmaceuticals to treat, cure or mitigate 
different mental disorders. Considering the side 
effects caused by intake of common prescribed 
drug it is of fundamental importance the repla-
cement for natural based products that has less 
safety concerns with equivalent or better efficacy 
parameters. 
Methods
It was performed a qualitative systematic review 
of articles about incidents biopharmaceuticals 
used as drugs to treat, cure or mitigate different 
mental disorders published in electronic databases 
previously selected. It was conducted a search in 
the literature through the online databases Pub-
Med, Scopus and Science Direct, by limiting itself 
to articles published between January 1, 2009 to 
August 25, 2014.
The reason to limit the search between 2009 and 
2014 was because before this period, the number 
of published works were little expressive and at 
the same time not addressed directly the use of 
biopharmaceuticals on mental disorders.
The following terms were used for, searching on 
the Databases:
1) Biopharmaceuticals (Keyword)
2) Biologics (Keyword)
3)  Mental disorders (Medical Subject Headings 
[MeSH]).
The analysis of the article followed eligibility cri-
teria previously determined. The survey was carried 
out in six phases: 1 and 3; 2 and 3 on each database 
(Figure 1).
On PubMed, we used the filters MeSH Terms, 
Title/Abstract, Publication Dates, Free Full Text, 
and English on the strategy 1 and 3; and MeSH 
Terms, Title/Abstract, Publication dates, Full text, 
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and English in the strategy 2 and 3 (Figure 1). On 
Scopus, we used the filters All, Title/Abstract/Ke-
ywords, Publication Dates, English and Document 
Type (Article), on the strategy 1 and 3; Abstract, 
Publication Dates, English and Document Type 
(Article), on the strategy 2 and 3 (Figure 1). On 
Science Direct, we used the filters Publication 
Dates, Journals and Full text on the strategy 1 
and 3; Publication Dates, Journals, All Fields and 
Abstract/Title/Keywords on the strategy 2 and 3 
(Figure 1).
It was adopted the following inclusion criteria: 
(1) written publications in English (2) studies invol-
ving the of use of biopharmaceuticals on mental 
Figure 1: Flow charting showing study selection for this review.
Abbreviations: MeSH, Medical Subject Headings
InternatIonal archIves of MedIcIne
Section: PSychiatry and Mental health 
Issn: 1755-7682 
2015
Vol. 8 No. 188
doi: 10.3823/1787
© Under License of Creative Commons Attribution 3.0 License 5
disorders; (3) original articles with full text acces-
sible through the Portal de Periódicos CAPES (The 
Coordenação de Aperfeiçoamento de Pessoal de 
Nível Superior) a virtual library connected to the 
Brazilian Ministry of education with content res-
tricted to authorized users; and (5) prospective 
or retrospective observational studies (descriptive 
or analytical, except for case studies), experimen-
tal or almost experimental. The exclusion criteria 
were: (1) other study designs, e.g. case reports, 
case series, literature reviews and comments; (2) 
non-original studies, including editorials, reviews, 
forewords, short communications and letters to 
the editor. 
Each article was read in its entirety, and the in-
formation was entered in a spreadsheet that inclu-
ded authors, year of publication, the study sam-
ple description, key data, and databases. To better 
analyze the data, the following stage involved the 
comparison between the articles and the division of 
the results obtained from the reading of each one 
of them in four main categories: Relevant plants 
worldwide, Relationship of mechanisms of action of 
potential biopharmaceuticals and their correlated di-
seases, Comparison among biopharmaceuticals and 
other drugs well established on the market, Genetic 
variations and gene therapy perspectives related to 
mental disorders. 
Results 
Initially, the aforementioned search strategies re-
sulted in 339 references. After browsing the title 
and abstract of the retrieved citations for eligibility 
based on study inclusion criteria, 319 articles were 
excluded and 20 articles were further retrieved and 
included in the final sample (Figure 1). 
Table 1 provides an overview of all studies inclu-
ded in the final sample and of all data elements 
used during the data analysis process. The 20 
studies were distributed into the previously deter-
mined four categories as follows: Relevant plants 
worldwide [10, 15, 16, 18, 23, 44, 46, 58, 59, 
60] (ten studies); Relationship of mechanisms of 
action of potential biopharmaceuticals and their 
correlated diseases [10, 11, 15, 20, 23, 44, 46, 58, 
59] (nine studies), Comparison among biopharma-
ceuticals and other drugs well established on the 
market [10, 11, 23, 44, 46] (five studies), Genetic 
variations and gene therapy perspectives related 
to mental disorders [9, 28, 58, 93, 96, 100, 134] 
(seven studies).
Among the 20 studies, some studies were re-
ferenced in more than one category. The catego-
rization of studies aims to a better organizational 
quality systematic review and it is not compulsory 
that each article must be referenced only in their 
respective category.
Discussion
Relevant plants worldwide 
Ethnopharmacology has led to the discovery of bo-
tanical medicines or natural products useful in psy-
chiatric disorders such as anxiety and depression, 
sleep disorders, and dementias [15]. A combina-
tion of screening approaches to evaluate a selected 
sample of Amazonian ethnomedicines for indica-
tions of CNS activities that may have therapeutic 
applications for the treatment of cognitive deficits 
was used by McKenna et al [15]. Additionally, Hy-
pericum perforatum commonly known as St. Johns 
Wort; is the most well-known herbal product avai-
lable over the counter [10]. Previous studies have 
shown that a number of plants from this family, 
including Salvia officinalis, Salvia elegans, Salvia 
reuterana, and Scutellaria baicalensis have shown 
anti-anxiety activity [10, 43]. Stachystibetica is dis-
tributed in the tropical and subtropical regions of 
the world, including in Tibet, China, India, etc. In 
India, it is found in the cold desert regions of the 
Ladakh Valley and in the mountains of Himachal 
Pradesh [10]. 
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Table 1. A new perspective of biopharmaceuticals and mental disorders treatment: a systematic review. Studies and main findings.
Authors Journal Sample Main Findings
Kumar 
et al [10] 
(2013)
Chinese Journal of 
Natural Medicines
60 rats Methanolic extracts (200 and 400 mg·kg−1) of the root, stem, leaf and whole plant of Stachys tibetica Vatke and 
diazepam (DZ) increased the time spent and the number of entries in the open arm significantly (**P < 0.01), while they 
decreased the time spent and the number of entries in the closed arm. These allied parameters helped to assess the 
anxiolytic potential of Stachys tibetica Vatke. The results strongly justify the use of this plant for the treatment of anxiety.
Yamaguchi 
et al [46] 
(2012)
Journal of 
Ethnopharmacology
Male Wistar/ST 
rats
These findings suggested that yokukansan has anxiolytic effects on anxiety-like behaviors induced by both innate fear and 
memory-dependent fear.
Gaoa 
et al [16] 
(2011)
Journal of 
Ethnopharmacology
56 male Sprague-
Dawley rats
The significant difference in metabolic profiling was observed from model group compared with drug-dose group by 
using the Principal Component Analysis (PCA), indicating the recovery effect of XYS on Chronic Unpredictable mild Stress 
(CUMS) rats.
Bisong SA, 
Brown R, 
Osim EE. 
[60] (2010)
Journal of 
Ethnopharmacology
90 male CD-1 
strain of mice
Root bark extract from Rauwolfia vomitoria produced better behavioural effects with less distortion in motor coordination 
when compared to chlorpromazine and so has a great potential as an alternative antipsychotic agent compared to 
chlorpromazine.
Kasper 
et al [23] 
(2010)
International Clinical 
Psychopharmacology
221 adults 
suffering from 
anxiety disorders.
Lavandula oil preparation silexan is both efficacious and safe for the relief of anxiety disorder not otherwise specified. It 
has a clinically meaningful anxiolytic effect and alleviates anxiety related to disturbed sleep.
Dai et al 
[20] 
(2010)
Journal of 
Ethnopharmacology
48 male Sprague–
Dawley
In term of anti-depression effect, high dose xiaoyaosan was the most effective and amitriptyline equaled middle dose 
xiaoyaosan as shown by metabolomics strategy and behavior tests.
Zhou et al 
[18] (2010)
Pharmacology, 
biochemistry, and 
behavior.
Male Kunming 
mice
It was demonstrated that acute and sub-chronic administration of extracts of Fructus Akabiae produced antidepressant-
like effects. The results suggest that the extracts of Fructus Akebiae exert antidepressant activity.
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Authors Journal Sample Main Findings
Guilmatre 
et al [92] 
(2009)
Archives of General 
Psychiatry
28 candidate loci Recurrent or overlapping Copy Number Variations (CNVs) were found in cases at 39.3% of the selected loci. The collective 
frequency of CNVs at these loci is significantly increased in cases with autism, in cases with schizophrenia, and in cases 
with mental retardation compared with controls (P <.001, P =.01, and P =.001, respectively, Fisher exact test). Individual 
significance (P =.02 without correction for multiple testing) was reached for the association between autism and a 
350-kilobase deletion located at 22q11 and spanning the PRODH and DGCR6 genes.
McKenna 
et al [15] 
(2011)
Journal of 
Ethnopharmacology
Approximately 
300 Amazonian 
species
Ninety-one samples displayed ≥60% inhibition of radioligand binding activity in receptor assays; 135 samples displayed 
agonist or antagonist activity (or both) in functional assays
Teranishi 
et al [44] 
(2013)
Journal of Clinical 
Psychopharma-
cology.
90 patients with 
dementia
Mean Neuropsychiatric Inventory in Nursing Home Version total score decreased in all 3 drug groups, with no significant 
between-group differences. Mini-Mental State Examination and Functional Independence Measure scores did not change 
significantly. Drug-Induced Extra-Pyramidal Symptoms Scale scores did not change in the yokukansan and fluvoxamine 
groups, but increased significantly in the risperidone group. Risperidone, yokukansan, and fluvoxamine were equally 
effective in the treatment of BPSD in elderly patients. However, yokukansan or fluvoxamine for BPSD showed a more 
favorable profile in tolerability compared with risperidone. 
Knorle R 
[59] (2012)
Journal of Neural 
Transmission
S.scardica extracts EC50 values were in the range of 30–40 lg/ml. Inhibition of the human serotonin transporter by the methanol extract was 
even more effective (EC50 1.4 lg/ml). Combining Sideritis ethanol extract and fluvoxamine resulted in a leftward shift of 
the fluvoxamine concentration–response curve. 
Umezu T 
[11] (2012)
Phytotherapy 
research: PTR
20 plant-derived 
essential oils (EOs)
Essential oils of peppermint and chamomile exhibited CNS stimulant-like effects; that is, they increased the response rate 
(number of shuttlings/min) of the avoidance response. Linden also increased the response rate, however, the effect was 
not dose-dependent. In contrast, EOs of orange, grapefruit, and cypress exhibited CNS depressant-like effects; that is, they 
decreased the response rate of the avoidance response. Essential oils of eucalyptus and rose decreased the avoidance rate 
(number of avoidance responses/number of avoidance trials) without affecting the response rate, indicating that they may 
exhibit some CNS acting effects. Essential oils of 12 other plants, including juniper, patchouli, geranium, jasmine, clary sage, 
neroli, lavender, lemon, ylang-ylang, niaouli, vetivert and frankincense had no effect on the avoidance response in mice. 
Hope et al 
[93] (2013)
Schizophrenia 
Research
322 patients with 
schizophrenia 
spectrum and 
bipolar disorder
After controlling for confounders, IL-1Ra and TNF-R1 were independently associated with Global Assessment of 
Functioning (GAF), and significantly correlated with Positive and Negative Syndrome Scale (PANSS) negative and positive, 
respectively. In addition, Il-1Ra was associated with premorbid adjustment scale (PAS), and sTNF-R1 with number of 
hospitalizations and psychotic episodes. Von Willebrand factor (VWf) was significantly corre lated with psychotic episodes, 
osteoprotegerin (OPG) with hospitalizations and IL-6 with history of psychosis. Linear regression analysis showed that GAF 
remained associated with sTNF-R1 and IL-1Ra with PANSS, after controlling for the other clinical measures. 
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Authors Journal Sample Main Findings
Tost et al 
[96] (2013)
Neuropsychophar-
macology
85 healthy 
Caucasian adults
Prior imaging genetics work, are consistent with complex effects of the BDNF Val66Met polymorphism on human brain 
structure, and may serve to generate hypotheses about variation in white matter microstructure in mental disorders 
associated with this variant.
Wang et al 
[28] (2012)
Molecular brain ACC neurons 
of adult mice 
overexpressing 
dominant active 
CREB mutant.
CREB contributes to the regulation of fragile X mental retardation protein.
Unternaehrer 
et al [100] 
(2012)
Nature Transl 
Psychiatry
76 adults-43 
women and 
33 men-aged 
between 61 and 
67 years
They found different DNA methylation states in the OXTR when comparing pre-stress, post-stress and 90-min follow-up 
stress measurement.
Corvin AP 
[9] (2010)
Cell adhesion & 
Migration
28 CAM genes ASDs and psychotic disorders may involve overlapping molecular aetiology where an accumulation of small effects from 
many common genetic risk variants or more highly penetrant mutations induce neuronal dysconnectivity by disrupting 
CAM function.
Sharkar 
et al [1] 
(2013)
Journal of Herbs 111 medicinal 
plants belonging 
to 62 families
Assessments of reported ethnomedicinal activity indicated that these plant species can potentially lead to the discovery of 
novel compounds of pharmacological interest.
Camacho-
Garcia et 
al [134] 
(2012)
Neurobiology of 
Diseasea
86 cases with 
autism and mental 
retardation and 
200 controls
They Reported the identification of four novel independent mutations that affect nearby positions in two regions of the 
gene/protein. These mutations cosegregate with different psychiatric disorders other than autism and mental retardation, 
such as psychosis and attention-deficit/hyperactivity disorder.
Sarris et al 
[58] (2013)
Journal of Clinical 
Psychopharmacology.
75 participants 
with GAD and no 
comorbid mood 
disorder
Standardized kava may be a moderately effective short-term option for the treatment of generalized anxiety disorder 
(GAD). Furthermore, specific GABA transporter polymorphisms appear to potentially modify anxiolytic response to kava.
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Yokukansan was developed in 1555 by Xue Kai 
and is one of the traditional Japanese medicines 
called kampo medicines in Japan [44, 45]. In the 
traditional use of yokukansan, it is useful for cu-
ring screaming attacks, sleep terrors and hypnicm-
yoclonia, especially in children [46] .It has been 
approved by the Ministry of Health, Labour and 
Welfare of Japan as a remedy for neurosis, insom-
nia, and irritability in children [44, 45]. In addition, 
yokukansan could be useful as one of the thera-
peutic drugs for the treatment of anxiety disorders 
and various mental disorders that have comorbid 
anxiety [46]. 
Xiaoyaosan (XYS), a well-known formula for re-
lieving depression, was originated from the book 
of “Taiping HuiminHejiJufang” in Song Dynasty 
(960-1279 AD), consisting of Radix Bupleuri, Radix 
Angelicae Sinensis, Radix Paeoniae Alba, Rhizoma 
Atractylodis Macrocephalae, Poria, Radix Glycy-
rrhizae, HerbaMenthae, and Rhizoma Zingiberis 
Recens with dose proportion of 6:6:6:6:6:3:2:2. In 
traditional Chinese medicine (TCM), the XYS de-
coction exerts various actions, including smoothing 
the liver, improving the circulation of Qi to relieve 
depression, strengthening the spleen, and nouris-
hing blood [16]. 
The German Commission E, an independent body 
appointed by the German Federal Health Agency in 
1978 to analyze and assess the information regar-
ding herbal medicines compiled from evidence ba-
sed as well as from traditional sources, has approved 
lavender flowers (Lavandulaeflos) for the treatment 
of restlessness, insomnia, and nervous disorders of 
the intestines [23, 47]. Psychological and psychiatric 
research involving lavender preparations has been 
focused on the drugs’ relaxing, anxiolytic and mood 
alleviating [23, 48-56]. 
Fructus Akebiae is the dry fruit of Akebiaequina-
ta (THUNB.) DECNE., a well-known medicinal plant 
widely distributed in China. It is recorded in the 
Compendium of Materia Medica that Fructus Ake-
biae is the major ingredient in some complex pres-
criptions for treating mental disorders and cogniti-
ve and behavioral deficits, including insomnia and 
dreaminess, loss of memory, paraphasia, phobia, 
and depressive disorder etc. Previous studies re-
veal that the genus Akebiae contains more than 
thirty types of triterpenoid saponins, and most of 
these triterpenoid saponins comprise hederagenin 
[18, 57]. 
Kava is a South Pacific plant medicine with tra-
ditional cultural use as an inebriant and modern 
clinical use as an anxiolytic. Kava extracts are, 
however, still currently available in the United Sta-
tes, Australia, and the South Pacific Islands. In 
response to safety concerns, the World Health Or-
ganization commissioned a report assessing the 
risk of kava products. Recommendations from this 
report suggest that products from water-based 
suspensions should be developed and tested in 
clinical studies and that these formulations should 
preferentially be used over acetonic and ethanolic 
extracts [58]. 
Within the Mediterranean area the pharmacolo-
gical profile of Sideritis scardica extracts as triple 
monoamine reuptake inhibitors suggests their use 
in the phytochemical therapy of mental disorders 
associated with a malfunctioning monoaminergic 
neurotransmission, such as anxiety disorders, ma-
jor depression, attention-deficit hyperactivity di-
sorder, mental impairment or neurodegenerative 
diseases. The genus Sideritis (Lamiaceae) compri-
ses about 150 species distributed mainly in the 
Mediterranean area and in the moderate zones 
of Asia [59]. 
One of the herbs used for the treatment of psy-
chiatric disorders in Nigeria is Rauwolfia vomitoria 
Afzelius which belongs to the family Apocynaceae 
[60, 61]. Herbal preparations of Rauwolfia vomito-
ria are used by traditional medicine practitioners in 
the treatment of mental disorder, as demonstrated 
by decreased anxiety related behaviour in the mice 
[60]. 
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Relationship of mechanisms of action of 
potential biopharmaceuticals and their 
correlated diseases
It has been reported that EOs of lavender [11, 62, 
63], roman chamomile [11, 64], neroli [11, 63, 65] 
and sandalwood [11, 63] might exhibit CNS depres-
sant-like effects, whereas EOs of lemon [11, 66], 
jasmine [11, 67], rosemary [11, 68] and sage [11, 69] 
might exhibit CNS stimulant-like effects [11]. 
The serotonin system mediates a wide variety 
of functions including perception, emotion, atten-
tion, and cognition [15, 70]. Serotonin receptors 
putatively involved in the mediation of cognitive 
functions include 5HT1A, 5HT2A, 5HT4, and 5HT6; 
not surprisingly these are promising targets for 
development of cognition-enhancing medications 
[15, 71, 72]. 
A disturbance in the glutamatergic system may 
be associated with Behavioral and Psychological 
Symptoms of Dementia (BPSD). Yokukansan im-
proved glutamate uptake and inhibited glutama-
te-induced neuronal death in a dose-dependent 
manner, thereby exerting a neuroprotective effect 
by improvement of the dysfunction of astrocytes.It 
seems that protection of the neuronal cells by gluta-
mate uptake may be involved in the mechanisms of 
yokukansan [44]. However, yokukansan produced 
anxiolytic effects mediated through 5-HT1A recep-
tors on the learned fear [46]. 
The extracts of different parts of Stachystibetica 
had different anxiolytic effects, and the effects may 
be due to the presence of different classes of chemi-
cal constituents and variation in their concentration. 
The other reason for the effects may be due to the 
synergism and antagonism actions and competence 
towards the receptors like benzodiazepines, sero-
tonins, GABA, dopamines, adrenergic, cholinergic, 
histamines, etc [10]. 
Lavender oil potentiated the binding of GABA on 
GABAA receptors in Xenopus oocytes [23, 73] and 
showed spasmolytic activity in a guinea-pig ileum 
smooth muscle preparation [20, 74]. 
Numerous in vivo and in vitro models suggest 
several mechanisms by which kava may mediate 
a broad spectrum of psychopharmacologic ac-
tions from its psychoactive constituents, known 
as kavalactones. These actions include blockade 
of voltage-gated sodium ion channels, reduced 
excitatory neurotransmitter release from blockade 
of calcium ion channels, enhanced ligand binding 
to F-aminobutyric acid (GABA) type A receptors, 
reversible inhibition of monoamine oxidase B, in-
hibition of cyclooxygenase, and reduced neuronal 
reuptake of dopamine and noradrenaline [58, 75-
84]. 
Recently, the effects of Sideritis preparations on 
the central nervous system have come into the 
focus of research. Aqueous and alcoholic extracts 
of S. scardica have turned out to act as triple 
monoamine reuptake inhibitors in vitro, inhibi-
ting the uptake of serotonin, noradrenaline and 
dopamine by their respective transporters. These 
findings allow new perspectives on the potential 
use of S. scardica extracts, as he pharmaceutical 
industry has made considerable efforts to develop 
chemically defined triple monoamine reuptake in-
hibitors [59]. 
Comparison among biopharmaceuticals 
and other drugs well established on the 
market
According to Teranishiet al [44], severe adverse 
events were experienced by 11 patients: 5 in the 
risperidone group, 3 in the yokukansan group, 
and 3 in the fluvoxamine group. Improvements in 
Neuropsychiatric Inventory in Nursing Home Ver-
sion (NPI-NH) score suggested that risperidone, 
yokukansan, and fluvoxamine were equally effica-
cious in treating BPSD in this elderly population. 
Yokukansan also reduced the NPI-NH scores. None 
of risperidone, yokukansan, or fluvoxamine impai-
red cognitive function measured by Mini-Mental 
State Examination (MMSE) and daily life function 
measured by Functional Independence Measure 
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(FIM) throughout the 8-week period. Yokukansan 
and fluvoxamine would be generally better tole-
rated compared with antipsychotic drugs, such as 
risperidone [44]. 
Peppermint (MINT) and Chamomile (CHA) ex-
hibited CNS stimulant-like effects; that is, they 
increased the response rate. Linden also increa-
sed the response rate. Orange (ORA), grapefruit 
(GRAP) and cypress (CYP) exhibited CNS depres-
sant-like effects; that is, they decreased the res-
ponse rate. The eucalyptus (EUC) and rose (ROS) 
oils might also act as CNS depressants because 
they decreased the avoidance rate. However, the-
se two EOs are distinguishable from typical CNS 
depressants examined in the present study, inclu-
ding chlorpromazine (CPZ), haloperidol (HAL), dia-
zepam (DZ) and physostigmine (PHYS), as EUC and 
ROS did not produce any effects on the response 
rate [11]. 
Kumar et al [10] have reported that All of the 
extracts of Stachystibetica at a dose of 200 and 
400 mg·kg−1 significantly increased the percentage 
of time spent and the arm entries in the open arms, 
and decreased the number of entries and duration 
of time spent in the closed arms. In a similar fas-
hion, the standard drug, diazepam, increased the 
percentage of time spent and the percentage of 
arm entries in the open arms. Additionally, all of 
the extracts and DZ decreased the time spent at 
the center of the maze or the latency along with 
closed arm returns and the DZ and methanol ex-
tract of the whole plant of Stachystibetica (SMW) 
did not show the fecal bolus while other groups 
had reduced fecal bolus (**P < 0.01), as compared 
to control, showing that the behavioral alterations 
induced by the extracts in the Elevated Plus Maze 
(EPM) are consistent with an anxiolytic effect, similar 
to that of diazepam [10]. 
The anxiolytic action of lavender is supported 
by several small or medium-sized clinical trials 
[23, 45-52]. Furthermore, were demonstrated 
that well-defined preparation from Lavandula 
angustifolia in an immediate release capsule, si-
lexan, administered orally at a dose of 80 mg/day 
is both efficacious and safe for relief of anxiety 
disorder not otherwise specified (NOS). The drug 
was determined to have a meaningful anxiolytic 
effect and to alleviate anxiety related disturbances 
of sleep while improving the physical and mental 
well-being. Taking into account that the tolerabili-
ty of the herbal extract was on one level with pla-
cebo, the absence of unwanted sedative effects 
and the convenient once daily administration of 
silexan may emerge as a gentle therapeutic alter-
native in the treatment of anxiety [23]. 
Genetic variations and gene therapy 
perspectives related to mental disorders
Recently, Guilmatre et al [92] collected information 
in different sources about candidates for a possible 
gene therapy and their pathways, elucidating which 
location of a gene can be responsible for each rela-
ted mental disorder [92]. 
The underlying pathological mechanisms of seve-
re mental disorders are still largely unknown. The 
disorders are highly heritable [93, 94] with complex 
genetic and environmental interactions involved [93, 
95]. However, the specific mechanisms involved re-
main elusive [93]. 
In recent years, imaging genetics has emerged 
as a popular approach with which to explore the 
effects of genetic variation on measures of brain 
structure and function, but initial studies are of-
ten followed by inconsistent results. Among others, 
BDNF Val66Met has previously been implicated as 
genetic risk factor for bipolar disorder, schizophre-
niadepression [96, 97-99]. Additionally, Tost et al 
[96] have found evidence of BDNF Val66Met ge-
notype effects on white matter microstructure in 
healthy young Caucasian adults manifesting as re-
ductions in measures of coherent spatial orientation 
of white matter in Val/Val homozygotes, which may 
serve to generate hypotheses about the changes 
in white matter structure in disorders that have 
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been associated with the Val allele, even though 
between-study differences in methods may contri-
bute to the observed heterogeneity in genetic as-
sociation findings [96]. 
Disruption of a number of these genes (inclu-
ding NRXN1, CNTNAP2 and CASK) are known to 
cause diverse neurodevelopmental brain disorder 
phenotypes including schizophrenia, autism, lear-
ning disability and specific language disorder. Taken 
together these studies bring the cell adhesion mo-
lecule (CAM) pathway sharply into focus for more 
comprehensive DNA sequencing to identify the cri-
tical genes, and investigate their relationships and 
interaction with environmental risk factors in the 
expression of many seemingly different neurode-
velopmental disorders [9]. 
DNA methylation is an epigenetic mechanism 
related to mental and physical health and disease. 
Aberrant DNA methylation has been implicated in 
the etiology of various mental disorders including, 
depression, psychotic disorders, post-traumatic 
stress disorder, autism, eating disorders, and subs-
tance dependence but also has an important role 
in the pathology of physical illnesses, such as can-
cer. Thereby DNA methylation provides a biological 
basis for gene–environment interactions relevant 
to mental health, animal and human studies have 
found that early life experiences can alter DNA 
methylation and affect gene expression and be-
havior [100, 101-131]. 
It was found methylation stress-associated DNA 
changes in one of two OXTR target sequences 
but not in the assessed target sequence of BDNF, 
suggesting a considerable variation in the sensi-
tivity of short-term DNA methylation responses 
among different stress-related genes. For OXTR1, 
we found an increase in DNA methylation from 
pre-stress to post-stress and a decrease from post-
stress to follow-up. In OXTR2, methylation decrea-
sed from post-stress to follow-up only. Notably, 
in OXTR1 the time-associated changes, as well as 
the difference from post-stress to follow up, re-
mained significant even after controlling for blood 
cell count [100]. 
Regarding BDNF, our results suggest that in the 
periphery, DNA methylation in BDNF remains stable 
after a short and non-recurring psychosocial stres-
sor. Previous studies found lifelong and transgene-
rational perpetuation of changes in BDNF methyla-
tion after early-life adversity [100, 131]. Fuchikami 
et al [132] recently suggested DNA methylation of 
BDNF in peripheral blood as a diagnostic biomarker 
of major depression [100, 132]. These results and 
our finding implicate that BDNF methylation has a 
long-term, rather than a short-term, role in stress 
adaptation [100]. 
The added novel finding of the study, concer-
ning a possible association of specific genetic va-
riants within the SLC6A1 locus encoding GABA 
transporter modify response, is intriguing; kava is 
known to affect anxiolytic activity from the kava-
lactone constituents effects on GABA pathways. 
Although not directly related to pharmacodyna-
mics drug response, a study by Thoeringer et 
al [133] found that the frequency of the GABA 
transporter rs2697153 G-allele is significantly 
more prevalent in people with anxiety disorders, 
with the protective effect of those with A-alleles 
having an odds ratio of 2.17 (95% confidence 
interval, 1.46Y3.24) [58, 133]. Interestingly, our 
findings suggest that the number of A-alleles co-
rresponds with the likelihood of a favorable res-
ponse to kava [58]. 
In the last years, mutations in neurexin and neu-
roligin genes have been associated with Autism 
Spectrum Disorders (ASD), such as the identifica-
tion of four novel mutations of NRXN1β in a sample 
of 86 patients with autism and Mental Retardation 
that in larger populations combined with functio-
nal analysis of ASD-associated mutations will help 
clarify the disease mechanisms [134]. 
Fragile X syndrome is caused by lack of fragile X 
mental retardation protein (FMRP) due to silencing 
of the FMR1 gene. The metabotropic glutamate 
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receptors (mGluRs) in the central nervous system 
contribute to higher brain functions including lear-
ning/memory, mental disorders and persistent pain. 
The transcription factor cyclic AMP-responsive ele-
ment binding protein (CREB) is involved in impor-
tant neuronal functions, such as synaptic plasticity 
and neuronal survival. It was shown in previous 
studies that stimulation of Group I mGluRsupregu-
lated FMRP and activated CREB in anterior cingu-
late cortex (ACC), a key region for brain cognitive 
and executive functions, suggesting that activation 
of Group I mGluRs may upregulate FMRP through 
CREB signaling pathway. Therefore, was proposed 
that CREB is the key transcription factor in regula-
tion of FMRP by Group I mGluRs in ACC neurons, 
and may help to further elucidate the molecular 
and cellular mechanisms underlying fragile X syn-
drome [28]. 
Conclusion
Many plants and natural entities have been used 
as sources of biomolecules that may be used as 
biopharmaceuticals to treat, cure or mitigate mental 
disorders. In this review, no approved biopharma-
ceutical was found within the last 5 years to treat 
mental disorders, which highlights the need of in-
vesting in this area, supported by the fact that there 
is a potential field where biomolecules may serve as 
new drugs to treat those disorders.
Several biomarkers have been related to men-
tal disorders with regards to their level and the 
severity of disease, such as sTNF-R1 and IL-1Ra17. 
Those markers may be targets of biologics that 
would help to keep the level of those molecu-
les normal. Additionally, many genes have been 
suggested as signatures of mental disorders, po-
tentially opening avenues for gene therapy or the-
rapies based on maintaining normal epigenetic 
profile in humans.
The popular medicine has an important role in 
providing natural sources that have been known 
as active compounds used to treat mental disor-
ders. However, those substances have not been 
largely characterized and studied at a clinical level, 
demonstrating the field of biopharmaceuticals pro-
vides an unexplored area to be developed. There-
fore, this field is significant and can revolute the 
future of current medicines used to treat mental 
disorders. 
Acknowledgments
We are grateful to the Suicidology Research group 
- Federal University of Ceará (UFC) / National Coun-
cil for Scientific and Technological Development 
(CNPq). We would also like to thank the Scientific 
Writing Lab (LABESCI) – Faculty of Medicine, Federal 
University of Cariri (UFCA), to the LABESCI – Biote-
chnology, UFC.
Conflict of interest
The authors have no conflicts of interest or financial 
ties to report. 
References
 1. PriyankaSharkar, M. MizanurRahman, GaziZiaul et al. 
“Ethnomedicinal importance of the plants in villages in 
Kushtiasador and Mirpurupozila, Bangladesh”. Journal of Herbs, 
Spices & Medicinal Plants (2013) 19, 401-417.
 2. Farnsworth, N. R., and D. D. Soejarto. 1991. Global importance 
of medicinal plants. In O. Akerele, V. Heywood, and H. Synge, 
eds., The Conservation of Medicinal Plants. Cambridge University 
Press, Cambridge, UK.pp. 25-51.
 3. Pei, S. 2001. Ethnobotanical approaches of traditional 
medicine studies: Some experiences from Asia. Pharma. Bot. 
39: 74-79.
 4. Balick, J. M., and P. A. Cox. 1996. Plants, People and Culture: 
The Science of Ethnobotany. Scientific American Library, New 
York. 228 pp.
 5. Gilani, A. H., and A. U. Rahman. 2005. Trends in ethnopharma-
cology. J. Ethnopharmacol. 100: 43-49.
 6. Masum, G., Z. H, P. Sharkar, M. A. Nayeem, M. Rahman, and M. 
M. Rahman. 2013. Medicinal plants used by Kabiraj of fourteen 
villages in Jhenaidah district, Bangladesh. Global J. Res. Med. 
Plants Indigen. Med. 2(1): 10-22.
InternatIonal archIves of MedIcIne
Section: PSychiatry and Mental health 
Issn: 1755-7682 J
2015
Vol. 8 No. 188
doi: 10.3823/1787
This article is available at: www.intarchmed.com and www.medbrary.com 14
 7. Rahmatullah, M, D. Ferdausi, M. A. H. Mollik, R. Jahan, M. H. 
Chowdhur, and W. M. Haque. 2010. A survey of medicinal plants 
used by Kavirajasof Chalna area, Khulna District, Bangladesh. 
Afr. J. Trade. Com. Alter. Med. 7: 91-97.
 8. Comer, M., and E. Debus. 1996. A partnership: Biotechnology, 
biopharmaceuticals and biodiversity. In F. Di Castri and T. 
Younnes, eds., Biodiversity. Scienceand Development. CAB 
International, Oxford. pp. 488-499.
 9. Aiden P. Corvin. “Neuronal cell adhesion genes”. Cell Adhesion 
& Migration (2010) 4: 4, 511-514.
 10. Dinesh Kumar, Zulfiqar Ali Bhat, Vijender Kumar et al. “Anti-
anxiety activity of StachystibeticaVatke”. Chinese Journal of 
Natural Medicines 2013, 11(3): 0240−0244.
 11. ToyoshiUmezu. “Evaluation of the Effects of Plant-derived 
Essential Oils on Central Nervous System Function Using 
Discrete Shuttle-type Conditioned Avoidance Response in 
Mice”.Phytother. Res. 2012. 26: 884-891.
 12. Balchin ML. 1997. Essential oils and ‘aromatherapy’: their 
modern role in healing. J R Soc Health 117: 324-329.
 13. Buckle J. 1999. Use of aromatherapy as a complementary 
treatment of chronic pain. AlternTher 5: 42-51.
 14. Perry N, Perry E. 2006. Aromatherapy in the management 
of psychiatric disorders-Clinical and neuropharmacological 
perspectives.CNS Drugs 20: 257-280.
 15. Dennis J. McKenna, Juan M. Ruiz, Thomas R. Hoy et al. 
“Receptor screening technologies in the evaluation of 
Amazonian ethnomedicines with potential applications to 
cognitive deficits”. Journal of Ethnopharmacology 134 (2011) 
475-492. 
 16. XiaoxiaGaoa, XingyuZhenga, Zhenyu Li et al. “Metabonomic 
study on chronic unpredictable mild stress and intervention 
effects of Xiaoyaosan in rats using gas chromatography coupled 
with mass spectrometry”. Journal of Ethnopharmacology 137 
(2011) 690-699.
 17. Peet M, Murphy B, Shay J, Horrobin D. “Depletion of omega-3 
fatty acid levels in red blood cell membranes of depressive 
patients”. Biological Psychiatry 43 (2003), 315-319.
 18. Dan Zhou, Hong Jin, Huan-Bing Lin et al. “Antidepressant 
effect of the extracts from FructusAkebiae”. Pharmacology, 
Biochemistry and Behavior 94 (2010) 488-495.
 19. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, 
Malberg JE, et al. Innovative approaches for the development 
of antidepressant drugs: current and future strategies. NeuroRx 
2005;2: 590-611.
 20. Yuntao Dai, Zhenyu Li, Liming Xue et al. “Metabolomics study on 
the anti-depression effect of xiaoyaosan on rat model of chronic 
unpredictable mild stress”. Journal of Ethnopharmacology 128 
(2010) 482-489.
 21. Xu, Z.W., Wu, L.L., Ya, V.C., 2003. The experimental research 
on anti-depression effects of xiaoyaosan decoction and 
danzhixiaoyaosan decoction.Acta Chinese Medicine and 
Pharmacology 31, 61.
 22. Zhao, X.J., Zhang, Y., Meng, X.L., Yin, P.Y., Deng, C., Chen, 
J., Wang, Z., Xu, G.W., 2008a. Effect of a traditional Chinese 
medicine preparation Xindi soft capsule on rat model of 
acute blood stasis: a urinary metabonomics study based 
on liquid chromatography-mass spectrometry. Journal of 
Chromatography B 873, 151-158.
 23. Siegfried Kasper, Markus Gastpar, Walter E. Muller et al. “Silexan, 
an orally administered Lavandula oil preparation, is effective in 
the treatment of ‘subsyndromal’ anxiety disorder: a randomized, 
double-blind, placebo controlled trial”. International Clinical 
Psychopharmacology 2010, 25: 277-287.
 24. Hidalgo RB, Davidson JR (2001). Generalized anxiety disorder. 
An important clinical concern.Med Clin North Am 85: 691-710.
 25. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, 
Eshleman S, et al. (1994). Lifetime and 12-month prevalence 
of DSM-III-R psychiatric disorders in the United States. Results 
from the National Comorbidity Survey. Arch Gen Psychiatry 51: 
8-19.
 26. Andrews G, Carter GL (2001).What people say about their 
general practitioners’ treatment of anxiety and depression. Med 
J Aust 175 (Suppl): S48-S51.
 27. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Zohar 
J, et al. (2008). World Federation of Societies of Biological 
Psychiatry (WFSBP) guidelines for the pharmacological 
treatment of anxiety, obsessive-compulsive and posttraumatic 
stress disorders-first revision.World J Biol Psychiatry 9: 248-312.
 28. Hansen Wang, Yoshikazu Morishita, Daiki Miura et al. “Roles 
of CREB in the regulation of FMRP by group I metabotropic 
glutamate receptors in cingulate cortex”. Molecular Brain 2012, 
5: 27.
 29. Belmonte MK, Bourgeron T: Fragile X syndrome and autism at 
the intersection of genetic and neural networks. Nat Neurosci 
2006, 9(10): 1221-1225.
 30. Bhakar AL, Dolen G, Bear MF: The Pathophysiology of Fragile 
X (and What It Teaches Us about Synapses). Annu Rev Neurosci 
2012, 2012: 2012.
 31. Feng Y, Zhang F, Lokey LK, Chastain JL, Lakkis L, Eberhart D, 
Warren ST: Translational suppression by trinucleotide repeat 
expansion at FMR1. Science 1995, 268(5211): 731-734.
 32. Garber KB, Visootsak J, Warren ST: Fragile X syndrome. Eur J 
Hum Genet 2008, 16(6): 666-672.
 33. Huber K: Fragile X syndrome: molecular mechanisms of cognitive 
dysfunction. Am J Psychiatry 2007, 164(4): 556.
 34. Jin P, Warren ST: New insights into fragile X syndrome: from 
molecules to neurobehaviors. Trends BiochemSci 2003, 28(3): 
152-158.
InternatIonal archIves of MedIcIne
Section: PSychiatry and Mental health 
Issn: 1755-7682 
2015
Vol. 8 No. 188
doi: 10.3823/1787
© Under License of Creative Commons Attribution 3.0 License 15
 35. Santoro MR, Bray SM, Warren ST: Molecular mechanisms of 
fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 
2011, 7: 219-245
 36. Krueger DD, Bear MF: Toward fulfilling the promise of molecular 
medicine in fragile X syndrome. Annu Rev Med 2011, 62: 411-
429
 37. Wang T, Bray SM, Warren ST: New perspectives on the biology 
of fragile X syndrome. CurrOpin Genet Dev 2012, 22(3): 256-
263.
 38. Fava M. Diagnosis and definition of treatment-resistant 
depression. Biol Psychiatry 2003;53: 649-59.
 39. Antai-Otong D. Antidepressant-induced insomnia: treatment 
options. PerspectPsychiatr Care 2004;40: 29-33.
 40. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction 
during double-blind treatment of major depression with 
reboxetine or paroxetine. J Psychopharmacol 2006;20: 91-6.
 41. Khurana RN, Baudendistel TE. Hypertensive crisis associated 
with venlafaxine. Am J Med 2003;115: 676-7.
 42. Park IY, Kim EJ, Park H, Fields K, Dunker AK, Kang C. Interaction 
between cardiac calsequestrin and drugs with known 
cardiotoxicity. MolPharmacol 2005;67: 97-104.
 43. D. Kumar et al. Effects of Stachystibetica essential oil in 
anxiety (2012). European Journal of Integrative Medicine 4(2) 
e169-e176.
 44. Mika Teranishi, Masatake Kurita, Satoshi Nishino et al. “Efficacy 
and Tolerability of Risperidone, Yokukansan, and Fluvoxamine 
for the Treatment of Behavioral and Psychological Symptoms of 
Dementia: A Blinded, Randomized Trial”. J ClinPsychopharmacol 
2013;33: 600 - 607. 
 45. Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A 
randomized, observer-blind, controlled trial of the traditional 
Chinese medicine yi-gan san for improvement of behavioral 
and psychological symptoms and activities of daily living in 
dementia patients. J Clin Psychiatry. 2005;66(2): 248Y252.
 46. Taku Yamaguchi, Aki Tsujimatsu, Haruko Kumamoto et al. 
“Anxiolytic effects of yokukansan, a traditional Japanese 
medicine, via serotonin 5-HT1A receptors on anxiety-related 
behaviors in rats experienced aversive stress”. Journal of 
Ethnopharmacology 143 (2012) 533-539.
 47. Bundesgesundheitsamt (1984). Monographie-Lavandulaeflos 
(Lavendelblu¨ ten).Bundesanzeiger 228 (December 5, 1984).
 48. Louis M, Kowalski SD (2002). Use of aromatherapy with hospice 
patients to decrease pain, anxiety, and depression and to 
promote an increased sense of well-being. Am J HospPalliat 
Care 19: 381-386.
 49. Motomura N, Sakurai A, Yotsuya Y (2001). Reduction of mental 
stress with lavender odorant.Percept Mot Skills 93: 713-718.
 50. Morris N (2002). The effects of lavender (Lavendulaangustifolium) 
baths on psychological well-being: two exploratory randomised 
control trials. Complement Ther Med 10: 223-228.
 51. Akhondzadeh S, Kashani L, Fotouhi A, Jarvandi S, Mobaseri 
M, Moin M, et al. (2003). Comparison of Lavandulaangustifolia 
Mill tincture and imipramine in the treatment of mild to 
moderate depression: a double-blind, randomized trial. 
ProgNeuropsychopharmacolBiol Psychiatry 27: 123-127.
 52. Field T, Diego M, Hernandez-Reif M, Cisneros W, Feijo L, Vera 
Y, et al. (2005). Lavender fragrance cleansing gel effects on 
relaxation. Int J Neurosci 115: 207-222.
 53. Lehrner J, Marwinski G, Lehr S, Johren P, Deecke L (2005). 
Ambient odors of orange and lavender reduce anxiety and 
improve mood in a dental office. PhysiolBehav 86: 92-95.
 54. Lin PW, Chan WC, Ng BF, Lam LC (2007). Efficacy of 
aromatherapy (Lavandulaangustifolia) as an intervention for 
agitated behaviours in Chinese older persons with dementia: 
a cross-over randomized trial. Int J Geriatr Psychiatry 22: 405-
410.
 55. Bradley BF, Brown SL, Chu S, Lea RW (2009). Effects of orally 
administered lavender essential oil on responses to anxiety-
provoking film clips. Hum Psychopharmacol 24: 319-330.
 56. McCaffrey R, Thomas DJ, Kinzelman AO (2009). The effects 
of lavender and rosemary essential oils on test-taking anxiety 
among graduate nursing students.Holist NursPract 23: 88-93.
 57. Jiang D, Gao QP, Shi SP, Tu PF. Triterpenoidsaponins from the 
fruits of Akebiaequinata. Chem Pharm Bull (Tokyo) 2006;54: 
595-7.
 58. Jerome Sarris, Con Stough, , Chad A. Bousman et al. “Kava in 
the Treatment of Generalized Anxiety Disorder A Double-Blind, 
Randomized, Placebo-Controlled Study” Journal of Clinical 
Psychopharmacology (2013) 33, 643-64.
 59. Rainer Knorle. “Extracts of Sideritisscardica as triple monoamine 
reuptake inhibitors”.J Neural Transm (2012) 119: 1477-1482.
 60. Sunday AgbaBisong, Richard Brown, EmeEffiomOsim. 
“Comparative effects of Rauwolfiavomitoria and chlorpromazine 
on locomotorbehaviour and anxiety in mice”. Journal of 
Ethnopharmacology 132 (2010) 334-339.
 61. Akpanabiatu, M.I., Umoh, I.B., Eyong, E.U., 2006. Influence 
of Rauwolfiavomitoria root bark on cardiac enzymes o normal 
Wistar albino rats. Recent Progress in Medicinal Plants 14, 273-
278.
 62. Buchbauer G, Jirovetz L, Jäger W. 1991. Aromatherapy: 
evidence for sedative effects of the essential oil of lavender 
after inhalation. Z Naturforsch 46c: 1967-1972. 
 63. Buchbauer G, Jirovetz L, Jäger W, Plank C, Dietrich H. 1993. 
Fragrance compounds and essential oils with sedative effects 
upon inhalation. J Pharm Sci 82: 660-664.
 64. Rossi T, Melegari M, Bianchi A, Albasini A, Vampa G, 1988. 
Sedative, anti-inflammatory and anti-diuretic effects induced 
in rats by essential oils of varieties of Anthemisnobilis: a 
comparative study. Pharmacol Res Commun 20(Suppl 5): 71-
74.
InternatIonal archIves of MedIcIne
Section: PSychiatry and Mental health 
Issn: 1755-7682 J
2015
Vol. 8 No. 188
doi: 10.3823/1787
This article is available at: www.intarchmed.com and www.medbrary.com 16
 65. Carvalho-Freitas MI, Costa M. 2002. Anxiolitic and sedative 
effects of extracts and essential oil of Cirusarutanium L. Biol 
Pharm Bull 25: 1629 - 1633.
 66. Komori T, Fujiwara R, Tanida M, Nomura J. 1995. Potential 
antidepressant effects of lemon odor in rats.Eur J 
Neuropsychopharmacol 5: 477 - 480
 67. Tsuchiya T, Tanida M, Uenoyama S, Nakayama Y. 1992. Effects of 
olfactory stimulation with jasmine and its component chemicals 
on the duration of pentobarbital-induced sleep in mice.Life Sci 
50: 1097-1102.
 68. Kovar KA, Gropper B, Friess D, Ammon HP. 1987. Blood levels 
of 1, 8-cineol and locomotor activity of mice after inhalation 
and oral administration of rosemary oil.Planta Med 53: 315-
318.
 69. Wake G, Court J, Pickering A, Lewis, R, Wilkins R, Perry E. 2000. 
CNS acetylcholine receptor activity in European medicinal plants 
traditionally used to improve failing memory. J Ethnopharmacol 
69: 105-114.
 70. Berger, M., Gray, J.A., Roth, B.L., 2009. The expanded biology 
of serotonin. Annual Review of Medicine 60, 355-366.
 71. Roth BL, Hanizavareh SM, Blum AE. 2004b. Serotonin 
receptors represent highly favorable molecular targets for 
cognitive enhancement in schizophrenia and other disorders. 
Psychopharmacology (Berlin) 174, 17 - 24. 
 72. Gray, J.A., Roth, B.L., 2007b. Molecular targets for treating 
cognitive dysfunctions in schizophrenia. Schizophrenia Bulletin 
33, 1100-1119.
 73. Aoshima H, Hamamoto K (1999). Potentiation of GABAA 
receptors expressed in Xenopus oocytes by perfume and 
phytoncid. BiosciBiotechnolBiochem 63: 743-748.
 74. Lis-Balchin M, Hart S (1999). Studies on the mode of action 
of the essential oil of lavender (Lavandulaangustifolia P. Miller).
Phytother Res 13: 540-542.
 75. 75, LaPorte E, Sarris J, Stough C, et al. Neurocognitive effects 
of kava (Piper methysticum): a systematic review. Hum 
Psychopharmacol. 2011;26(2): 102Y111.
 76. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract 
ingredients, (+)-methysticin and (+/j)-kavain inhibit voltage-
operated Na(+)-channels in rat CA1 hippocampal neurons. 
Neuroscience. 1997;81(2): 345Y351.
 77. Gleitz J, Beile A, Peters T. (+/-)-Kavain inhibits veratridine-
activated voltage-dependent Na(+)-channels in synaptosomes 
prepared from rat cerebral cortex. Neuropharmacology. 
1995;34(9): 1133Y1138.
 78. Martin HB, McCallum M, Stofer WD, et al. Kavain attenuates 
vascular contractility through inhibition of calcium channels. 
Planta Med. 2002;68(9): 784Y789.
 79. Walden J, von Wegerer J, Winter U, et al. Effects of kawain 
and dihydromethysticin on field potential changes in the 
hippocampus. ProgNeuropsychopharmacolBiol Psychiatry. 
1997;21(4): 697Y706.
 80. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract 
from Piper methysticum as modulator of the GABA binding site 
in different regions of rat brain. Psychopharmacology (Berl). 
1994;116(4): 469Y474.
 81. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B 
by kava pyrone-enriched extract from Piper methysticum 
Forster (kava-kava).Pharmacopsychiatry. 1998;31(5): 187Y192.
 82. Wu D, Yu L, Nair M, et al. Cyclooxygenase enzyme inhibitory 
compounds with antioxidant activities from Piper methysticum 
(kava kava) roots. Phytomedicine. 2002;9: 41Y47.
 83. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and 
individual kavapyrones on neurotransmitter levels in the nucleus 
accumbens of rats. ProgNeuropsychopharmacolBiol Psychiatry. 
1998;22(7): 1105Y1120.
 84. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition 
properties of kava pyrones. Planta Med. 1997;63(6): 548Y549
 85. Buckle J (1993). Aromatherapy. Nurs Times 89: 32-35.
 86. Dunn C, Sleep J, Collett D (1995). Sensing an improvement: 
an experimental study to evaluate the use of aromatherapy, 
massage and periods of rest in an intensive care unit. J AdvNurs 
21: 34-40.
 87. Hardy M, Kirk-Smith MD, Stretch DD (1995). Replacement of 
drug treatment for insomnia by ambient odour. Lancet 346: 
701.
 88. Hudson R (1996). Nursing: the value of lavender for rest and 
activity in the elderly patient. Complement Ther Med 4: 52-57.
 89. Wolfe N, Herzberg J (1996). Can aromatherapy oils promote 
sleep in severely demented patients? Int J Geriatr Psychiatry 11: 
926-927.
 90. Itai T, Amayasu H, Kuribayashi M, Kawamura N, Okada M, 
Momose A, et al. (2000). Psychological effects of aromatherapy 
on chronic hemodialysis patients.Psychiatry ClinNeurosci 54: 
393-397.
 91. Lehrner J, Marwinski G, Lehr S, Johren P, Deecke L (2005). 
Ambient odors of orange and lavender reduce anxiety and 
improve mood in a dental office. PhysiolBehav 86: 92-95.
 92. Audrey Guilmatre, ChristèleDubourg, Anne-Laure 
Mosca et al. “Recurrent Rearrangements in Synaptic and 
Neurodevelopmental Genes and Shared Biologic Pathways in 
Schizophrenia, Autism, and Mental Retardation”. Arch Gen 
Psychiatry. 2009;66(9): 947-956.
 93. Sigrun Hope, Thor Ueland, Nils Eiel Steen et al. “Interleukin 1 
receptor antagonist and soluble tumor necrosis factor receptor 
1 are associated with general severity and psychotic symptoms 
in schizophrenia and bipolar disorder”. Schizophrenia Research 
145 (2013) 36-42.
 94. Harrison, P.J., Weinberger, D.R., 2005. Schizophrenia genes, 
gene expression, and neuropathology: on the matter of their 
convergence. Mol. Psychiatry 10 (1), 40-68.
InternatIonal archIves of MedIcIne
Section: PSychiatry and Mental health 
Issn: 1755-7682 
2015
Vol. 8 No. 188
doi: 10.3823/1787
© Under License of Creative Commons Attribution 3.0 License 17
 95. Burmeister, M., McInnis, M.G., Zollner, S., 2008. Psychiatric 
genetics: progress amid controversy. Nat. Rev. Genet. 9 (7), 
527-540.
 96.  Heike Tost, TajvarAlam, Matthew Geramita et al. “Effects of the 
BDNF Val66Met Polymorphism on White Matter Microstructure 
in Healthy Adults”. Neuropsychopharmacology (2013) 38, 525-
532
 97.  Sklar P et al (2002). Family-based association study of 76 
candidate genes in bipolar disorder: BDNF is a potential risk 
locus. Brain-derived neutrophic factor. Mol Psychiatry 7: 579-
593.
 98.  Neves-Pereira M. et al (2005). BDNF gene is a risk factor for 
schizophrenia in a Scottish population. Mol Psychiatry 10: 208-
212.
 99.  Verhagen M. et al (2010). Meta-analysis of the BDNF Val66Met 
polymorphism in major depressive disorder: effects of gender 
and ethnicity. Mol Psychiatry 15: 260-271.
 100.  E Unternaehrer, P Luers, J Mill, E Dempster et al. “Dynamic 
changes in DNA methylation of stress-associated genes (OXTR, 
BDNF) after acute psychosocial stress”. Translational Psychiatry 
(2012) 2, 1-7.
 101.  Docherty S, Mill J. Epigenetic mechanisms as mediators of 
environmental risks for psychiatric disorders. Psychiatry 2008; 
7: 500-506.
 102.  Toyokawa S, Uddin M, Koenen KC, Galea S. How does the 
social environment ‘get into the mind’? Epigenetics at the 
intersection of social and psychiatric epidemiology.SocSci Med 
2012; 74: 67-74.
 103.  National Institute of Mental Health. National Institute of 
Mental Health Strategic Plan, 2008.
 104.  Scarano MI, Strazzullo M, Matarazzo MR, D’Esposito M. 
DNA methylation 40 years later: Its role in human health and 
disease. J Cell Physiol 2005; 204: 21-35.
 105.  Fuchikami M, Morinobu S, Segawa M, Yamawaki S. DNA 
methylation profiles of the BDNF gene in patients with major 
depression. Int J Neuropsychopharmacol 2010; 13: 147.
 106.  Olsson CA, Foley DL, Parkinson-Bates M, Byrnes G, McKenzie 
M, Patton GC et al. Prospects for epigenetic research within 
cohort studies of psychological disorder: a pilot investigation 
of a peripheral cell marker of epigenetic risk for depression. 
BiolPsychol 2010; 83: 159-165.
 107.  Rotter A, Asemann R, Decker A, Kornhuber J, Biermann T. 
Orexin expression and promoter-methylation in peripheral 
blood of patients suffering from major depressive disorder. J 
Affect Disord 2011; 131: 186-192.
 108.  Uddin M, Koenen KC, Aiello AE, Wildman DE. de los Santos R, 
Galea S. Epigenetic and inflammatory marker profiles associated 
with depression in a community-based epidemiologic sample. 
Psychol Med 2011; 41: 997-1007.
 109.  Mill J, Petronis A. Molecular studies of major depressive 
disorder: the epigenetic perspective. Mol Psychiatry 2007; 12: 
799-814.
 110.  Abdolmaleky HM. Reelinhypermethylation in schizophrenia 
and beyond. Int J Neuropsychopharmacol 2006; 9: S37.
 111.  Ghadirivasfi M, Nohesara S, Ahmadkhaniha HR, Eskandari 
MR, Mostafavi S, Thiagalingam S et al. Hypomethylation 
of the serotonin receptor type-2A gene (HTR2A) at T102C 
polymorphic site in DNA derived from the saliva of patients 
with schizophrenia and bipolar disorder. Am J Med Genet Part 
B 2011; 156B: 536-545.
 112.  Kuratomi G, Iwamoto K, Bundo M, Kusumi I, Kato N, Iwata 
N et al. Aberrant DNA methylation associated with bipolar 
disorder identified from discordant monozygotic twins. Mol 
Psychiatry 2008; 13: 429-441.
 113.  Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard 
L et al. Epigenomic profiling reveals DNA-methylation changes 
associated with major psychosis. Am J Hum Genet 2008; 82: 
696-711.
 114.  Shimabukuro M, Sasaki T, Imamura A, Tsujita T, Fuke C, 
Umekage T et al. Global hypomethylation of peripheral 
leukocyte DNA in male patients with schizophrenia: a potential 
link between epigenetics and schizophrenia. J Psychiatr Res 
2007; 41: 1042-1046.
 115.  Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades 
A, Kane F et al. Diseaseassociated epigenetic changes in 
monozygotic twins discordant for schizophrenia and bipolar 
disorder. Hum Mol Genet 2011; 20: 4786-4796.
 116.  Smith AK, Conneely KN, Kilaru V, Mercer KB, Weiss TE, Bradley 
B et al. Differential immune system DNA methylation and 
cytokine regulation in post-traumatic stress disorder. Am J 
Med Genet B Neuropsychiatr Genet 2011; 156B: 700-708.
 117.  Uddin M, Aiello AE, Wildman DE, Koenen KC, Pawelec G, de 
Los Santos R et al. Epigenetic and immune function profiles 
associated with posttraumatic stress disorder. ProcNatlAcadSci 
U S A 2010; 107: 9470-9475.
 118.  Schanen NC. Epigenetics of autism spectrum disorders.Hum 
Mol Genet 2006; 2: R138-R150.
 119.  Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global methylation 
profiling of lymphoblastoid cell lines reveals epigenetic 
contributions to autism spectrum disorders and a novel autism 
candidate gene, RORA, whose protein product is reduced in 
autistic brain. FASEB J 2010; 24: 3036-3051.
 120.  Frieling H, Romer KD, Scholz S, Mittelbach F, Wilhelm J, De 
Zwaan M et al. Epigenetic dysregulation of dopaminergic 
genes in eating disorders. Int J Eat Disord 2010; 43: 577-
583.
InternatIonal archIves of MedIcIne
Section: PSychiatry and Mental health 
Issn: 1755-7682 J
2015
Vol. 8 No. 188
doi: 10.3823/1787
This article is available at: www.intarchmed.com and www.medbrary.com 18
 121.  Frieling H, Bleich S, Otten J, Romer KD, Kornhuber J, 
de Zwaan M et al. Epigenetic downregulation of atrial 
natriuretic peptide but not vasopressin mRNA expression 
in females with eating disorders is related to impulsivity. 
Neuropsychopharmacology 2008; 33: 2605-2609. 22. Wong 
CC, Mill J, Fernandes C. Drugs and addiction: an introduction 
to epigenetics. Addiction 2011; 106: 480-489.
 122.  Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches 
mainstream oncology. Nat Med 2011; 17: 330-339.
 123.  Meaney MJ. Epigenetics and the biological definition of gene 
x environment interactions.Child Dev 2010; 81: 41-79.
 124.  Liu D, Diorio J, Tannenbaum B, Caldji C, Francis D, Freedman 
A et al. Maternal care, hippocampal glucocorticoid receptors, 
and hypothalamic-pituitary-adrenal responses to stress. 
Science 1997; 277: 1659-1662.
 125.  McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonte 
B, Szyf M et al. Epigenetic regulation of the glucocorticoid 
receptor in human brain associates with childhood abuse. Nat 
Neurosci 2009; 12: 342-348.
 126.  Mueller BR, Bale TL. Sex-specific programming of offspring 
emotionality after stress early in pregnancy.J Neurosci 2008; 
28: 9055-9065.
 127.  Radtke KM, Ruf M, Gunter HM, Dohrmann K, Schauer M, 
Meyer A et al. Transgenerational impact of intimate partner 
violence on methylation in the promoter of the glucocorticoid 
receptor. Transl Psychiatry 2011; 1.
 128.  Weaver ICG, Cervoni N, Champagne FA, D’Alessio AC, Sharma 
SS Jr et al. Epigenetic programming by maternal behavior. Nat 
Neurosci 2004; 7: 847-854.
 129.  Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, 
Devlin AM. Prenatal exposure to maternal depression, neonatal 
methylation of human glucocorticoid receptor gene (NR3C1) 
and infant cortisol stress responses. Epigenetics 2008; 3: 97-
106.
 130.  Spengler D, Murgatroyd C, Patchev AV, Wu Y, Micale V, 
Bockmuhl Y et al. Dynamic DNA methylation programs 
persistent adverse effects of early-life stress. Nat Neurosci 
2009; 12: 1559-U1108.
 131.  Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic 
influence of early-life adversity on the BDNF gene. Biol 
Psychiatry 2009; 65: 760-769.
 132.  Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki 
S, Ozaki N et al. DNA methylation profiles of the brain-derived 
neurotrophic factor (BDNF) gene as a potent diagnostic 
biomarker in major depression. Plos One 2011; 6: 8..
 133.  Thoeringer CK, Ripke S, Unschuld PG, et al. The GABA 
transporter 1 (SLC6A1): a novel candidate gene for anxiety 
disorders. J Neural Transm. 2009;116(6): 649Y657.
 134.  Rafael J. Camacho-Garcia, Ma. InmaculadaPlanelles, Mar 
Margalef et al. “Mutations affecting synaptic levels of 
neurexin-1β in autism and mental retardation”. Neurobiology 
of Disease 47 (2012) 135-143.
 
 
Where Doctors exchange clinical experiences, 
review their cases and share clinical knowledge.
You can also access lots of medical publications for
free. Join Now!
http://medicalia.org/
Comment on this article:
International Archives of Medicine is an open access journal 
publishing articles encompassing all aspects of medical scien-
ce and clinical practice. IAM is considered a megajournal with 
independent sections on all areas of medicine. IAM is a really 
international journal with authors and board members from all 
around the world. The journal is widely indexed and classified 
Q1 in category Medicine.
Publish with iMedPub
http://www.imed.pub
